In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedAlliance Inc. (Duplicate)

http://www.medalliance.com

Latest From MedAlliance Inc. (Duplicate)

Minute Insight: Cordis-MedAlliance Deal Formalized, Less Than One Year After Announcement

The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.

Minute Insights Cardiovascular

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Deals Market Intelligence

Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons

Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.

Exec Chats Clinical Trials

Cordis Makes First Big Post-Cardinal Deal: Agrees To Pay $1.1BN For MedAlliance

Cordis plans to acquire MedAlliance, the developer of the Selution SLR drug-eluting vascular balloon, for up to $1.135bn. As part of the deal, Cordis will immediately begin to co-promote Selution SLR in every market where it is available.

M & A Cardiovascular
See All

Company Information

  • Industry
  • Medical Devices
  • Services
UsernamePublicRestriction

Register